ImmunoGen, Inc. (IMU.F)
| Previous Close | 3.6225 |
| Open | 3.6235 |
| Bid | 3.6585 x 100000 |
| Ask | 3.7385 x 100000 |
| Day's Range | 3.6235 - 3.6235 |
| 52 Week Range | 3.3155 - 6.6820 |
| Volume | |
| Avg. Volume | 6 |
| Market Cap | 801.536M |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6500 |
| Earnings Date | Jul 28, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.79 |
- Business Wire
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
WALTHAM, Mass., May 10, 2022--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
- Motley Fool
ImmunoGen (IMGN) Q1 2022 Earnings Call Transcript
With me today are Mark Enyedy, our president and CEO; Anna Berkenblit, our chief medical officer; Kristen Harrington-Smith, our chief commercial officer; and Susan Altschuller, our CFO. As we progress toward our goal of becoming a global fully integrated oncology company, since the start of the year, we've also continued enrollment in the confirmatory Phase III MIRASOL and Phase II PICCOLO studies with mirv monotherapy, expanded our commercial team and accelerated launch preparations in anticipation of a mirv approval, further accrued patients in our pivotal CADENZA study of pivek and BPDCN, initiated expansion cohorts in both relapsed and frontline AML patients combining pivek with azacitidine and venetoclax and progressed our earlier-stage programs, IMGC936 and IMGN151.
- Zacks
ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates
ImmunoGen (IMGN) delivered earnings and revenue surprises of 52.38% and 56.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
